Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic

OBJECTIVES: Guidelines cautioned prescribing of tumour necrosis factor inhibitors (TNFi) to patients with rheumatoid arthritis and interstitial lung disease (RA-ILD) after reports of new or worsening of ILD. Less is known about outcomes among patients with RA-ILD who receive rituximab (RTX). This st...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:RMD Open
Egile Nagusiak: Druce, Katie L, Iqbal, Kundan, Watson, Kath D, Symmons, Deborah P M, Hyrich, Kimme L, Kelly, Clive
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2017
Gaiak:
Rheumatoid Arthritis
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604605/
https://ncbi.nlm.nih.gov/pubmed/28955489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2017-000473
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak